Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: A randomized controlled trial.

Competing Interests: Conflicts of interest Disclosures including pharmaceutical and device product(s): Murad Alam has no financial interests to declare in relation to the content of this article, and has not received payment or stock from Bonti, AbbVie, or any related organization. Domenico Vitarella, at the time of study conduct, was an employee of Bonti Inc and held Bonti stock prior to its acquisition by Allergan, an AbbVie Company. Wajdie Ahmad, at the time of study conduct, was a cofounder and chief operating officer of Bonti Inc and held Bonti stock prior to its acquisition by Allergan, an AbbVie Company. Susan Abushakra, at the time of study conduct, was a cofounder and chief medical officer of Bonti Inc, was co-inventor on several BoNT/E (EB-001) patents, and held Bonti stock prior to its acquisition by Allergan, an AbbVie Company. Cheri Mao is a former employee of AbbVie. Mitchell F. Brin is an employee of, and owns stock/stock options in, AbbVie. This product (BoNT/E; EB-001) is not labeled for the use under discussion.